GALT
Galectin Therapeutics Inc.NASDAQHealthcare$2.67-0.37%ClosedMarket Cap: $172.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.30
P/S
0.00
EV/EBITDA
0.00
DCF Value
$-1.86
FCF Yield
-14.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
25.6%
ROA
-157.9%
ROIC
-174.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-3.4M | $-5.5M | $-0.08 | — |
| FY 2025 | $0.00 | NaN% | $-20.1M | $-30.8M | $-0.48 | — |
| Q3 2025 | $0.00 | NaN% | $-4.2M | $-8.2M | $-0.13 | — |
| Q2 2025 | $0.00 | -Infinity% | $-4.6M | $-7.5M | $-0.12 | — |
| Q1 2025 | $0.00 | -Infinity% | $-7.9M | $-9.6M | $-0.15 | — |
| Q4 2024 | $0.00 | -Infinity% | $-12.4M | $-12.0M | $-0.19 | — |
| FY 2024 | $0.00 | -Infinity% | $-42.4M | $-47.0M | $-0.76 | — |
| Q3 2024 | $0.00 | -Infinity% | $-9.1M | $-11.2M | $-0.18 | — |
| Q2 2024 | $0.00 | -Infinity% | $-11.3M | $-12.4M | $-0.20 | — |
| Q1 2024 | $0.00 | -Infinity% | $-9.6M | $-11.5M | $-0.19 | — |
| Q4 2023 | $0.00 | -Infinity% | $-9.6M | $-10.0M | $-0.16 | — |
| FY 2023 | $0.00 | -Infinity% | $-38.1M | $-41.1M | $-0.74 | — |